By Dr Charlotte Rose Lemech

Conference Abstracts

Lemech C; Spira A; Sommerhalder D; Fu S; Ge F; Mu H; Yang Y; Qiu Y; Chen J; Shi R; Zhu Z; Xu R, 2026, 'Abstract CT092: A Phase 1a/1b, first-in-human study of an ADC targeting ADAM9 (DB-1317) in participants with selected advanced or metastatic solid tumors', in Cancer Research, American Association for Cancer Research (AACR), Vol. 86, pp. ct092 - ct092, http://dx.doi.org/10.1158/1538-7445.am2026-ct092

Tarhini AA; Chen M; Liu J; Monga V; Atkinson V; Piha-Paul SA; Chmielowski B; Herzberg B; Lemech C; Bhave P; Kichenadasse G; Falchook G; Mehnert J; Vandross A; Salkeni M; McKean M; Wages D; Kennedy AM; Ryan MB; Clark J; Nanah A; Fossler MJ; Komarnitsky P; Puzanov I, 2026, 'Abstract CT129: Preliminary results from a Phase 1a/b dose-escalation and expansion trial of the pan-RAF-MEK molecular glue NST-628 in patients (pts) with advanced or refractory RAF, KRAS, and NRAS-mutant solid tumors', in Cancer Research, American Association for Cancer Research (AACR), Vol. 86, pp. ct129 - ct129, http://dx.doi.org/10.1158/1538-7445.am2026-ct129

Lemech C; Humphries T; Biachi de Castria T; Cercek A; Overman M; Kummar S; Baldini C; Tabernero J; Hansen A; Nagrial A; Roberts K; Joshi R; Ahern E; Orr D; Al Hallak N; Van Tine BA; Waller D; Nabhan S; Drew A; Ballas M, 2025, 'Abstract B003: Orally administered MOMA-341 as monotherapy or combination therapy in participants with advanced or metastatic solid tumors: Phase 1 study design', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 24, pp. b003 - b003, http://dx.doi.org/10.1158/1535-7163.targ-25-b003

Lemech C; Coward J; Gao B; Park JJW; Zhou C; Moore M; Frentzas S; Gan HK; Wang J; Wang Q; Fang T; Dai H; Yue Z; La Y; Shi Q; Yang JJ, 2025, '1545P CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: An open-label, multicenter, phase I first-in-human study', in Annals of Oncology, Elsevier, Vol. 36, pp. s923, http://dx.doi.org/10.1016/j.annonc.2025.08.2176

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Alvarez EC; Yang JC-H; Ascierto PA; Pulla MP; Freeman D; Song X; Gainer SD; Mitchell P; Achour I; Subramaniam DS; Im S-A, 2022, 'Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. ct016 - ct016, http://dx.doi.org/10.1158/1538-7445.am2022-ct016

Lee DH; Roohullah A; Cho BC; Lemech CR; de Souza PL; Millward M; Choi JY; Park KE; Kim NY; Kim E; Lee S; Kim Y; Shin Y; Han J-Y, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3105 - 3105, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3105

Strickler JH; Satake H; Hollebecque A; Sunakawa Y; Tomasini P; Bajor DL; Schuler MH; Yaeger R; George TJ; Garrido-Laguna I; Coveler AL; Vincent MD; Falchook GS; Burns TF; Rha SY; Lemech CR; Juric D; Jafarinasabian P; Tran Q; Hong DS, 2022, 'First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 360490 - 360490, http://dx.doi.org/10.1200/jco.2022.40.36_suppl.360490

Lee DH; Roohullah A; Cho BC; Lee S-H; Lemech C; de Souza P; Millward M; Choi J; Park KE; Kim E; Kim NY; Shin YK; Han J-Y, 2022, '1197TiP A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation', in Annals of Oncology, Elsevier, Vol. 33, pp. s1096, http://dx.doi.org/10.1016/j.annonc.2022.07.1320

Markman B; Day D; Park JJW; Coward J; Bishnoi S; Kotasek D; Eek R; Brown MP; Lemech C; Kuo J; Prawira A; Strother R; Zhang Q; Wang L; Chen R; Ma Y; Qin Z; Tse A, 2020, 'Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S722 - S722, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.1177

Preprints

Gavagna G; Clifton-Bligh R; Lemech C; Williams S; Elefantis E; Nair H; Farrugia A, 2020, Intravenous Immunoglobulin Rich in Neutralising Antibodies to SARS-CoV-2 as a Passive Immunity Modality in Healthy Individuals at Risk of Infection With COVID-19: Study Protocol for an Open Label, Active Control Phase 1/2 Study., http://dx.doi.org/10.21203/rs.3.rs-137186/v1

Thoms JAI; Yan F; Hampton HR; Davidson S; Joshi S; Saw J; Sarowar CH; Lim XY; Nunez AC; Kakadia PM; Bhuyan GS; Zou X; Nguyen M; Ghodousi ES; Koch FC; Vafaee F; Pickford R; Raftery MJ; Hough S; Buckland G; Bailey M; Ghodke Y; Absar N; Vaughan L; Pasalic L; Fong CY; Kenealy M; Hiwase DK; Stoddart RI; Mohammed S; Lee L; Passam FH; Larsen SR; Spring KJ; Skarratt KK; Rebeiro P; Presgrave P; Stevenson WS; Ling S; Tiley C; Fuller SJ; Roncolato F; Enjeti AK; Hoenemann D; Lemech C; Jolly CJ; Bohlander SK; Curtis DJ; Wong JWH; Unnikrishnan A; Hertzberg M; Olivier J; Polizzotto MN; Pimanda JE, Clinical Response to Azacitidine in Myelodysplastic Neoplasms is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor cells in vivo, http://dx.doi.org/10.1101/2024.07.19.24310679

Other

Liu J; Farrow M; Hsing SS; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson AO; Park JJW; Rodrigues A; Chan WY; Wei J; Cohen J; Underhill CR; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, Data from Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance, http://dx.doi.org/10.1158/1078-0432.c.8715322

Liu J; Farrow M; Hsing SS; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson AO; Park JJW; Rodrigues A; Chan WY; Wei J; Cohen J; Underhill CR; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, Supplementary Data 1 from Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance, http://dx.doi.org/10.1158/1078-0432.33775921

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Data from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.c.8600817

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Figure S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014559

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Figure S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014556

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Figure S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014553

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014550

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Figure S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014547

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Methods S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014544

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Table S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014541

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Table S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014538

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Table S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014535

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014532

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Table S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014529

Back to profile page